Ready for Transfer

Small Molecule Inhibitors of Drug-Resistant Forms of HIV-1 Integrase

RFT image

Laboratory: National Cancer Institute (NCI)

Technology: Small Molecule Inhibitors of Drug-Resistant Forms of HIV-1 Integrase 

Opportunity: NCI is seeking partners to help develop these small molecule compounds for therapeutic use. The lab is offering an in-license for potential partners to apply for under a Cooperative Research and Development Agreement (CRADA) to conduct pre-clinical studies.

Details: Researchers at NCI recently discovered small molecule compounds that contain 1-hydroxy-2-oxo-1, 8-naphthyridine moieties that demonstrate effective activity against comprehensive and varied groups of integrase strand transfer inhibitors (INSTIs)-resistant mutants of HIV-1 integrase. According to the NIH, INSTIs are currently used as an integral part of prophylactic antiretroviral therapy, preventing HIV-1 infection from progressing to AIDS.

Benefits: As the FDA recently approved three INSTIs for use in antiretroviral regimens, these inhibitors are currently the only INSTI effective against drug-resistant mutants of HIV-1 integrase.

Potential Applications: This technology can be applied for HIV therapeutics for drug-resistant compounds of HIV-1 integrase.

Contact: For more information on collaboration opportunities for this technology, contact Lauren Nguyen-Antczak, Ph.D., J.D., at lauren.nguyen-antczak@nih.gov.